What do we know about occult hepatitis B virus infection?

Francesca Saffioti, Giovanni Raimondo

Abstract


Occult hepatitis B virus (HBV) infection (OBI) is recognized as one of the phases in the natural history of chronic HBV infection and defines the persistence of HBV genomes in the hepatocytes of individuals testing negative for HBV surface antigen (HBsAg) and detectable or undetectable HBV DNA in the serum. Occasionally, OBI is related to the infection with mutant viruses producing a modified HBsAg undetectable by diagnostic kits or with replication-defective variants. However, in most cases OBI is due to replication-competent viruses that are strongly suppressed in their activities by the host’s defence mechanisms. Growing evidence indicates that genetic, epigenetic and post-transcriptional mechanisms may be involved in the control of HBV activities and in the OBI occurrence.  OBI may be involved in several different clinical contexts, which can be grouped in four main categories: 1) transmission of the “occult” virus (mainly, through blood transfusion and orthotopic liver transplantation from OBI donors) causing classic forms of hepatitis B in the HBV naïve recipients; 2) reactivation of the HBV infection following the development of an immunosuppressive status, resulting in acute and occasionally fulminant hepatitis; 3) contribution to the progression of patients with various causes of liver disease toward cirrhosis; 4) involvement in hepatocarcinogenesis, likely through the maintenance of the direct and indirect pro-oncogenic properties typical of the overt HBV infection (such as the capacity to integrate in the host’s genome and to synthesize pro-oncogenic proteins) and by provoking a mild but persisting necroinflammation which favours cirrhosis development.

Keywords


Hepatitis B virus; Occult hepatitis B infection; Hepatitis B virus reactivation; Liver cirrhosis; Hepatocellular carcinoma

Full Text:

PDF

References


European Association for the Study of the Liver. (207). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 67(2), 370-98. doi: 10.1016/j.jhep.2017.03.021.

Raimondo, G., Allain, J.P., Brunetto, M.R., Buendia, M.A., Chen, D.S., Colombo, M., Craxì, A., Donato, F., Ferrari, C., Gaeta, G.B., Gerlich, W.H., Levrero, M., Locarnini, S., Michalak, T., Mondelli, M.U., Pawlotsky, J.M., Pollicino, T., Prati, D., Puoti, M., Samuel, D., Shouval, D., Smedile, A., Squadrito, G., Trépo, C., Villa, E., Will, H., Zanetti, A.R., Zoulim, F. (2008). Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol, 49(4), 652-7. doi: 10.1016/j.jhep.2008.07.014.

Torbenson, M., Thomas, D.L. (2002). Occult hepatitis B. Lancet Infect Dis, 2(8), 479-86.

Raimondo, G, Caccamo, G., Filomia, R., Pollicino, T. (2013). Occult HBV infection. Semin Immunopathol, 35(1), 39-52. doi: 10.1007/s00281-012-0327-7

Torbenson, M., Kannangai, R., Astemborski, J., Strathdee, S.A., Vlahov, D., Thomas, D.L. (2004) High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology, 39(1), 51-7. doi: 10.1002/hep.20025.

Raimondo, G., Pollicino, T., Cacciola, I., Squadrito, G. (2007). Occult hepatitis B virus infection. J Hepatol, 46(1), 160-70. doi: 10.1016/j.jhep.2006.10.007.

Wong, D.K., Huang, F.Y., Lai, C.L., Poon, R.T., Seto, W.K., Fung, J., Hung, I.F., Yuen, M.F. (2011). Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology., 54(3), 829-36. doi: 10.1002/hep.24551.

Shetty, K., Hussain, M., Nei, L., Reddy, K.R., Lok, A.S. (2008). Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl, 14(4), 534-40. doi: 10.1002/lt.21284.

Rabe, B., Vlachou, A., Pante, N., Helenius, A., Kann, M. (2003). Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A, 100(17), 9849-54. doi: 10.1073/pnas.1730940100.

Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., Dandri, M. (2009). Control of cccDNA function in hepatitis B virus infection. J Hepatol, 51(3), 581-92. doi: 10.1016/j.jhep.2009.05.022.

Zoulim, F. (2005). New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol, 42(3), 302-8. doi: 10.1016/j.jhep.2004.12.015.

Hollinger, F.B. (2008) Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion, 48(5), 1001-26. doi: 10.1111/j.1537-2995.2008.01701.x.

Wang, Y., Zhu, P., Qiu, J., Wang, J., Zhu, H., Zhu, Y., Zhang, L., Zhu, J., Liu, X., Dong, C. (2017). Identification and characterization of interferon signaling-related microRNAs in occult hepatitis B virus infection. Clin Epigenetics, 9:101. doi: 10.1186/s13148-017-0404-9.

El Chaar, M., Candotti, D., Crowther, R.A., Allain, J.P. (2010). Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology, 52(5), 1600-10. doi: 10.1002/hep.23886.

Hollinger, F.B., Sood, G. (2010). Occult hepatitis B virus infection: a covert operation. J Viral Hepat, 17(1), 1-15. doi: 10.1111/j.1365-2893.2009.01245.x.

Pollicino, T, Raffa, G., Costantino, L., Lisa, A., Campello, C., Squadrito, G., Levrero, M., Raimondo, G. (2007). Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology, 45(2), 277-85. doi: 10.1002/hep.21529.

Alexopoulou, A., Dourakis, S.P., Pandelidaki, H., Archimandritis, A.J., Karayiannis, P. (2006). Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol, 78(8), 1043-6. doi: 10.1002/jmv.20660.

Penna, A., Artini, M., Cavalli, A., Levrero, M., Bertoletti, A., Pilli, M., Chisari, F.V., Rehermann, B., Del Prete, G., Fiaccadori, F., Ferrari, C. (1996). Long-lasting memory T cell responses following selflimited acute hepatitis B. J Clin Invest., 98(5), 1185-94. doi: 10.1172/JCI118902.

Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F.V. (1996). The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic Tlymphocyte response. Nat Med, 2(10), 1104-8.

Bes, M., Vargas, V., Piron, M., Casamitjana, N., Esteban, J.I., Vilanova, N., Pinacho, A., Quer, J., Puig, L., Guardia, J., Sauleda, S. (2012). T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol, 56(4), 765-74. doi: 10.1016/j.jhep.2011.11.011.

Cohen Stuart, J.W., Velema, M., Schuurman, R., Boucher, C.A., Hoepelman, A.I. (2009). Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol, 81(3), 441-5. doi: 10.1002/jmv.21422.

Wands, J.R., Chura, C.M., Roll, F.J., Maddrey, W.C. (1975). Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology, 68(1), 105-12.

Lucifora, J., Durantel, D., Testoni, B., Hantz, O., Levrero, M., Zoulim, F. (2010). Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 51(1), 63-72. doi: 10.1002/hep.23230.

Pollicino, T., Belloni, L., Raffa, G., Pediconi, N., Squadrito, G., Raimondo, G., Levrero, M. (2006). Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology, 130(3), 823-37. doi: 10.1053/j.gastro.2006.01.001.

Vivekanandan, P., Thomas, D., Torbenson, M. (2009). Methylation regulates hepatitis B viral protein expression. J Infect Dis, 199(9), 1286-91. doi: 10.1086/597614.

Kaur, P., Paliwal, A., Durantel, D., Hainaut, P., Scoazec, J.Y., Zoulim, F., Chemin, I., Herceg, Z. (2010). DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis, 202(5), 700-4. doi: 10.1086/655398.

Raimondo, G., Caccamo, G., Saitta C. (2005). Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol, 4(2), 100-6.

Bellecave, P., Gouttenoire, J., Gajer, M., Brass, V., Koutsoudakis, G., Blum, H.E., Bartenschlager, R., Nassal, M., Moradpour, D. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. (2009). Hepatology, 50(1), 46-55. doi: 10.1002/hep.22951.

Tramuto, F., Maida, C.M., Colomba, G.M., Di Carlo, P., Vitale, F. (2013). Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int, 2013:859583. doi: 10.1155/2013/859583.

Oliveira, M.P., Lemes, P.S., Matos, M.A., Del-Rios, N.H., Carneiro, M.A., Silva, A.M., Lopes, C.L., Teles, S.A., Aires, R.S., Lago, B.V., Araujo, N.M., Martins, R.M.. (2016). Overt and occult hepatitis B virus infection among treatment-naive HIV-infected patients in Brazil. J Med Virol, 88(7), 1222-9. doi: 10.1002/jmv.24462

McClary, H., Koch, R., Chisari, F.V., Guidotti, L.G. (2000). Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med, 192(2), 289-94.

Omar, H.H., Taha, S.A., Hassan, W.H., Omar, H.H. (2017). Impact of schistosomiasis on increase incidence of occult hepatitis B in chronic hepatitis C patients in Egypt. J Infect Public Health. 10(6), 7615. doi: 10.1016/j.jiph.2016.11.010.

Allain, J.P., Cox, L. (2011). Challenges in hepatitis B detection among blood donors. Curr Opin Hematol, 18(6), 461-6. doi: 10.1097/MOH.0b013e32834bac10.

Candotti, D., Allain, J.P. (2009). Transfusion-transmitted hepatitis B virus infection. J Hepatol, 51(4), 798-809. doi: 10.1016/j.jhep.2009.05.020.

Stramer, S.L., Wend, U., Candotti, D., Foster, G.A., Hollinger, F.B., Dodd, R.Y., Allain, J.P., Gerlich, W. (2011). Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med, 364(3), 236-47. doi: 10.1056/NEJMoa1007644.

Chemin, I., Guillaud, O., Queyron, P.C., Trepo, C. (2009). Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol, 51(4), 824-5. doi: 10.1016/j.jhep.2009.06.007.

Kannangai, R., Vivekanandan, P., Netski, D., Meha, S., Kirk, G.D., Thomas, D.L., Torbenson, M. (2007). Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol, 39(2), 101-5. 10.1016/j.jcv.2007.03.006.

Cheung, C.K., Lo, C.M., Man, K., Lau, G.K. (2010). Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl, 6(11), 1314-23. doi: 10.1002/lt.22169.

Cholongitas, E., Papatheodoridis, G.V., Burroughs, A.K. (2010). Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol, 52(2), 272-9. doi: 10.3748/wjg.v19.i48.9189.

Toniutto, P., Minisini, R., Fabris, C., De Feo, T., Marangoni, F., Burlone, M., Avellini, C., Bitetto, D., Fornasiere, E., Fumolo, E., Baccarani, U., Pirisi, M. (2009). Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin Transplant, 23(2), 184-90. doi: 10.1111/j.1399-0012.2009.00964.x.

Angelico, M., Nardi, A., Marianelli, T., Caccamo, L., Romagnoli, R., Tisone, G., Pinna, A.D., Avolio, A.W., Fagiuoli, S., Burra, P., Strazzabosco, M., Costa, A.N. Liver Match Investigators. (2013). Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol, 58(4), 715-23.

Vitrone, M., Iossa, D., Rinaldi, L., Pafundi, P.C., Molaro, R., Parrella, A., Andini, R., Ragone, E., Maiello, C., Zampino, R., Durante-Mangoni, E. (2017). Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact. J Clin Virol, 96, 54-9. doi: 10.1016/j.jcv.2017.09.011.

Shouval, D., Shibolet, O. (2013). Immunosuppression and HBV reactivation. Semin Liver Dis, 33(2), 167-77. doi: 10.1055/s-0033-1345722.

Yeo, W., Chan, T.C., Leung, N.W., Lam, W.Y., Mo, F.K., Chu, M.T., Chan, H.L., Hui, E.P., Lei, K.I., Mok, T.S., Chan, P.K. (2009). Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol, 27(4), 605-11. doi: 10.1200/JCO.2008.18.0182.

Pei, S.N., Chen, C.H., Lee, C.M., Wang, M.C., Ma, M.C., Hu, T.H., Kuo, C.Y. (2010). Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol, 89(3), 255-62. doi: 10.1007/s00277-009-0806-7.

Hsu, C., Tsou, H.H., Lin, S.J., Wang, M.C., Yao, M., Hwang, W.L., Kao, W.Y., Chiu, C.F., Lin, S.F., Lin, J., Chang, C.S., Tien, H.F., Liu, T.W., Chen, P.J., Cheng, A.L. Taiwan Cooperative Oncology Group. (2014). Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology, 59(6), 2092-100. doi: 10.1002/hep.26718.

Coppola, N., Tonziello, G., Pisaturo, M., Messina, V., Guastafierro, S., Fiore, M., Iodice, V., Sagnelli, C., Stanzione, M., Capoluongo, N., Pasquale, G., Sagnelli, E. (2011). Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol, 83(11), 1909-16. doi: 10.1002/jmv.22199.

Grewal, J., Dellinger, C.A., Yung, W.K. (2007). Fatal reactivation of hepatitis B with temozolomide. N Engl J Med, 356(15), 1591-2. doi: 10.1056/NEJMc063696

Ritchie, D., Piekarz, R.L., Blombery, P., Karai, L.J., Pittaluga, S., Jaffe,E.S., Raffeld, M., Janik, J.E., Prince, H.M., Bates, S.E. (2009). Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica, 94(11), 1618-22.

Dominguez, N., Manzano, M.L., Munoz, R., Martin, A., Fernandez, I., Castellano, G. (2015). Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen. Leuk Lymphoma, 56(4), 1160-3. doi: 10.3109/10428194.2014.947978.

Seto, W.K., Chan, T.S., Hwang, Y.Y., Wong, D.K., Fung, J., Liu, K.S., Gill, H., Lam, Y.F., Lie, A.K., Lai, C.L., Kwong, Y.L., Yuen, M.F. (2014). Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol, 32(33), 3736-43.

Raimondo, G., Filomia, R., Maimone, S. (2014). Therapy of occult hepatitis B virus infection and prevention of reactivation. Intervirology, 57(3-4), 189-95. doi: 10.1159/000360943.

Sagnelli, C., Macera, M., Pisaturo, M., Zampino, R., Coppola, M., Sagnelli, E. (2016). Occult HBV infection in the oncohematological setting. Infection, 44(5), 575-82. doi: 10.1007/s15010-016-0891-1.

Onozawa,M., Hashino, S., Izumiyama, K., Kahata, K., Chuma, M., Mori, A., Kondo, T., Toyoshima, N., Ota, S., Kobayashi, S., Hige, S., Toubai, T., Tanaka, J., Imamura, M., Asaka, M. (2005). Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation, 79(5):616-9. doi: 0.1097/01.TP.0000151661.52601.FB.

Vigano, M., Vener, C., Lampertico, P., Annaloro, C., Pichoud, C., Zoulim, F., Facchetti, F., Poli, F., Scalamogna, M., Deliliers, G.L., Colombo, M. (2011). Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant, 46(1), 125-31. doi: 10.1038/bmt.2010.70.

Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P., Caraceni, P., Daniele, B., Di Marco, V., Fabrizi, F., Fagiuoli, S., Grossi, P., Lampertico, P., Meliconi, R., Mangia, A., Puoti, M., Raimondo, G., Smedile, A. Italian Association for the Study of the Liver. (2007). Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis, 39(5), 397-408. doi: 10.1016/j.dld.2006.12.017.

Bozza, C., Cinausero, M., Iacono, D., Puglisi, F. (2016). Hepatitis B and cancer: A practical guide for the oncologist. Crit Rev Oncol Hematol, 98, 137-46. doi: 10.1016/j.critrevonc.2015.10.017.

Voican, C.S., Mir, O., Loulergue, P., Dhooge, M., Brezault, C., Dréanic, J., Chaussade, S., Pol, S., Coriat, R. (2016). Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol, 27(12), 2172-84. doi: 10.1093/annonc/mdw414.

Federico, A, Brancaccio, G., Dallio, M., Iodice, P., Fabozzi, A., Del Prete, S., Ciardiello, F., Loguercio, C., Gaeta, G.B. (2017). Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis, 49(2), 197-201. doi: 10.1016/j.dld.2016.11.004.

Calvaruso, V., Ferraro, D., Licata, A., Bavetta, M.G., Petta, S., Bronte, F., Colomba, G., Craxì, A., Di Marco, V. (2017). HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2017 Jul 13. [Epub ahead of print]. doi: 10.1111/jvh.12754.

Sulkowski, M.S., Chuang, W.L., Kao, J.H., Yang, J.C., Gao, B., Brainard, D.M., Han, K.H., Gane, E. (2016). No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With LedipasvirSofosbuvir for Hepatitis C Virus Infection. Clin Infect Dis, 63(9), 1202-4. doi: 10.1093/cid/ciw507.

Wang, C., Ji, D., Chen, J., Shao, Q., Li, B., Liu, J., Wu, V., Wong, A., Wang, Y., Zhang, X., Lu, L., Wong, C., Tsang, S., Zhang, Z., Sun, J., Hou, J., Chen, G., Lau, G. (2017). Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol, 15(1), 132-6. doi: 10.1016/j.cgh.2016.06.023.

Huang, Y.H., Hsiao, L.T., Hong, Y.C., Chiou, T.J., Yu, Y.B., Gau, J.P., Liu, C.Y., Yang, M.H., Tzeng, C.H., Lee, P.C., Lin, H.C., Lee, S.D. (2013). Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol, 31(22), 2765-72. doi: 10.1200/JCO.2012.48.5938.

Wursthorn, K., Wedemeyer, H., Manns, M.P. (2010). Managing HBV in patients with impaired immunity. Gut, 59(10), 1430-45. doi: 10.1136/gut.2009.195834.

Muraishi, J., Shibata, M., Honma, Y., Hiura, M., Abe, S., Harada, M. (2017). Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med, 56(15), 1967-71. doi: 10.2169/internalmedicine.56.8233.

European Association For The Study Of The Liver. (2009) EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol, 50, 227-42. doi: 10.1016/j.jhep.2008.10.001.

Mori, S., Fujiyama, S. (2015). Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol, 21(36), 10274-89. doi: 10.3748/wjg.v21.i36.10274.

Squadrito, G., Spinella, R., Raimondo, G. (2014). The clinical significance of occult HBV infection. Ann Gastroenterol, 27(1), 15-9.

Blackberg, J., Kidd-Ljunggren, K. (2000). Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol, 33(6), 992-7.

Yuki, N., Nagaoka, T., Yamashiro, M., Mochizuki, K., Kaneko, A., Yamamoto, K., Omura, M., Hikiji, K., Kato, M. (2003). Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology, 37(5), 1172-9. doi: 10.1053/jhep.2003.50171.

Raimondo, G., Pollicino, T., Squadrito, G. (2005). What is the clinical impact of occult hepatitis B virus infection? Lancet. 365(9460):638-40. doi: 10.1016/S0140-6736(05)17961-6.

Covolo, L., Pollicino, T., Raimondo, G., Donato, F. (2013). Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis, 45(3), 238-44. doi: 10.1016/j.dld.2012.09.021.

Pollicino, T., Raimondo, G. (2014). Occult hepatitis B infection. J Hepatol, 61(3), 688-9. doi: 10.1016/j.jhep.2014.04.036.

Raimondo, G. (2001). Occult hepatitis B virus infection and liver disease: fact or fiction? J Hepatol, 34(3), 471-3.

Squadrito, G., Cacciola, I., Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. (2013). J Hepatol, 59(4), 696-700. doi: 10.1016/j.jhep.2013.05.043.

Saitta, C., Tripodi, G., Barbera, A., Bertuccio, A., Smedile, A., Ciancio, A., Raffa, G., Sangiovanni, A., Navarra, G., Raimondo, G., Pollicino, T. (2015). Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int, 35(10), 2311-7.

Shi, Y., Wu, Y.H., Wu, W., Zhang, W.J., Yang, J., Chen, Z. (2012). Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int, 32(2), 231-40. doi: 10.1111/j.1478-3231.2011.02481.x.

Chen, Y., Williams, V., Filippova, M., Filippov, V., Duerksen-Hughes, P. (2014). Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers (Basel), 6(4), 2155-86. doi: 10.3390/cancers6042155.

Chemin, I., Zoulim, F. (2009). Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett, 286(1), 52-9. doi: 10.1016/j.canlet.2008.12.003.

Fwu, C.W., Chien, Y.C., You, S.L., Nelson, K.E., Kirk, G.D., Kuo, H.S., Feinleib, M., Chen, C.J. (2011). Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology, 53(4), 1217-25. doi: 10.1002/hep.24150.

Marcucci, F., Mele, A., Spada, E., Candido, A., Bianco, E., Pulsoni, A., Chionne, P., Madonna, E., Cotichini, R., Barbui, A., De Renzo, A., Dore, F., Iannitto, E., Liso, V., Martino, B., Montanaro, M., Pagano, L., Musto, P., Rapicetta, M. (2006). High prevalence of hepatitis B virus infection in B-cell nonHodgkin's lymphoma. Haematologica, 91(4), 554-7.

Tanaka, M., Tanaka, H., Tsukuma, H., Ioka, A., Oshima, A., Nakahara, T. (2010). Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat, 17(10), 742-8. doi: 10.1111/j.1365-2893.2009.01243.x.

Perumal, V., Wang, J., Thuluvath, P., Choti, M., Torbenson, M. (2006). Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol, 37(9), 1211-6. 10.1016/j.humpath.2006.04.012.

Rossi, D., Sala, L., Minisini, R., Fabris, C., Falleti, E., Cerri, M., Burlone, M.E., Toniutto, P., Gaidano, G., Pirisi, M. (2009). Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma, 50(4), 604-11. doi: 10.1080/10428190902777673.




DOI: https://doi.org/10.6092/1828-6550/APMB.105.2.2017.SD2

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Francesca Saffioti, Giovanni Raimondo

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.